NASDAQ:PSTI - Pluristem Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $9.88
Forecasted Upside: 170.55 %
Number of Analysts: 4
Breakdown:
0 Sell Ratings
1 Hold Ratings
3 Buy Ratings
0 Strong Buy Ratings

^$3.65 As of 05/14/2021 01:00 AM ET

▲ +0.11 (3.11%)

1 month | 3 months | 12 months

Get New Pluristem Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for PSTI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PSTI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$9.88

▲ +170.55% Upside Potential

This price target is based on 4 analysts offering 12 month price targets for Pluristem Therapeutics in the last 3 months. The average price target is $9.88, with a high forecast of $12.50 and a low forecast of $6.00. The average price target represents a 170.55% upside from the last price of $3.65.

Buy

The current consensus among 4 polled investment analysts is to buy stock in Pluristem Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/23/2019

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/21/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/21/2020

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

8/19/2020

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

11/17/2020

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

2/15/2021

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

4/16/2021

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

5/16/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
5/10/2021	Alliance Global Partners	Initiated Coverage	Buy	$12.50	N/A	i
5/4/2021	Alliance Global Partners	Initiated Coverage	Buy	$12.50	Low	i
12/10/2020	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$6.00	High	i Rating by Chris Howerton at Jefferies Financial Group Inc.
12/7/2020	HC Wainwright	Reiterated Rating	Buy	$15.50 ➝ $9.00	High	i Rating by S. Ramakanth at HC Wainwright
10/9/2020	Dawson James	Reiterated Rating	Buy	$12.00	Low	i
7/24/2020	Jefferies Financial Group	Boost Price Target	Buy	$12.00 ➝ $16.00	Medium	i Rating by Chris Howerton at Jefferies Financial Group Inc.
6/19/2020	Jefferies Financial Group	Initiated Coverage	Buy	$12.00	High	i
5/15/2020	Maxim Group	Reiterated Rating	Buy	$12.00	Low	i Rating by Jason McCarthy at Maxim Group
5/14/2020	HC Wainwright	Reiterated Rating	Buy	$15.50	Medium	i Rating by Swayampakula Ramakanth at HC Wainwright
4/15/2020	Dawson James	Reiterated Rating	Buy		High	i Rating by Jason Kolbert at Dawson James
4/14/2020	Maxim Group	Initiated Coverage	Buy	$12.00	High	i Rating by Jason McCarthy at Maxim Group
4/8/2020	Maxim Group	Initiated Coverage	Buy	$8.00	High	i Rating by Jason McCarthy at Maxim Group
3/31/2020	Maxim Group	Initiated Coverage	Buy	$8.00	Medium	i Rating by Jason McCarthy at Maxim Group
3/18/2020	Maxim Group	Reiterated Rating	Buy	$8.00	High	i
2/10/2020	HC Wainwright	Reiterated Rating	Buy	$15.50	Low	i Rating by Swayampakula Ramakanth at HC Wainwright
12/16/2019	Dawson James	Initiated Coverage	Buy	$12.00	High	i
12/4/2019	Maxim Group	Reiterated Rating	Buy	$8.00	Low	i
11/13/2019	Maxim Group	Reiterated Rating	Buy	$8.00	High	i
11/13/2019	HC Wainwright	Reiterated Rating	Buy	$15.50	High	i
7/22/2019	LADENBURG THALM/SH SH	Initiated Coverage	Buy ➝ Buy		Low	i
4/24/2019	Maxim Group	Reiterated Rating	Buy	$30.00	Low	i Rating by Jason McCarthy at Maxim Group
12/17/2018	Maxim Group	Set Price Target	Buy	$30.00	Medium	i Rating by Jason McCarthy at Maxim Group
12/17/2018	HC Wainwright	Set Price Target	Buy	$40.00	Medium	i Rating by Swayampakula Ramakanth at HC Wainwright
12/4/2018	Maxim Group	Set Price Target	Buy	$30.00	High	i Rating by Jason McCarthy at Maxim Group
11/28/2018	Maxim Group	Reiterated Rating	Buy	$30.00	High	i Rating by Jason McCarthy at Maxim Group
11/12/2018	HC Wainwright	Set Price Target	Buy	$40.00	Low	i Rating by Swayampakula Ramakanth at HC Wainwright
9/28/2018	HC Wainwright	Reiterated Rating	Buy	$35.00	Low	i Rating by Swayampakula Ramakanth at HC Wainwright
7/31/2018	B. Riley	Initiated Coverage	Buy	$45.00	Low	i Rating by G. Zavoico at B. Riley
5/11/2018	HC Wainwright	Set Price Target	Buy	$40.00	High	i Rating by Swayampakula Ramakanth at HC Wainwright
5/10/2018	Maxim Group	Set Price Target	Buy	$30.00	Low	i Rating by Jason McCarthy at Maxim Group
5/1/2018	HC Wainwright	Set Price Target	Buy	$40.00	Medium	i Rating by Swayampakula Ramakanth at HC Wainwright
4/30/2018	Maxim Group	Set Price Target	Buy	$30.00	High	i Rating by Jason McCarthy at Maxim Group
4/23/2018	Maxim Group	Reiterated Rating	Buy	$30.00	Low	i Rating by Jason McCarthy at Maxim Group
2/21/2018	Maxim Group	Set Price Target	Buy	$30.00	Medium	i Rating by Jason Kolbert at Maxim Group
1/16/2018	HC Wainwright	Set Price Target	Buy	$40.00	Medium	i Rating by Swayampakula Ramakanth at HC Wainwright
11/9/2017	HC Wainwright	Reiterated Rating	Buy	$35.00	N/A	i Rating by S. Ramakanth at HC Wainwright
11/1/2017	Maxim Group	Set Price Target	Buy	$30.00	N/A	i Rating by Jason Kolbert at Maxim Group
10/26/2017	Maxim Group	Set Price Target	Buy	$30.00	N/A	i Rating by Jason Kolbert at Maxim Group
10/19/2017	Maxim Group	Set Price Target	Buy	$20.00	N/A	i Rating by Jason Kolbert at Maxim Group
10/6/2017	Seaport Global Securities	Reiterated Rating	Buy	$50.00	N/A	i Rating by V. Bernardino at Seaport Global Securities
10/2/2017	Maxim Group	Set Price Target	Buy	$20.00	Low	i Rating by Jason Kolbert at Maxim Group
9/19/2017	HC Wainwright	Reiterated Rating	Buy	$35.00	Low	i Rating by Swayampakula Ramakanth at HC Wainwright
9/6/2017	HC Wainwright	Reiterated Rating	Buy	$35.00	Medium	i Rating by Swayampakula Ramakanth at HC Wainwright
9/5/2017	Maxim Group	Reiterated Rating	Buy	$20.00	Medium	i Rating by Jason Kolbert at Maxim Group
8/17/2017	HC Wainwright	Set Price Target	Buy	$40.00	Medium	i Rating by Swayampakula Ramakanth at HC Wainwright
8/16/2017	Maxim Group	Set Price Target	Buy	$20.00	Medium	i Rating by Jason Kolbert at Maxim Group
7/10/2017	Maxim Group	Set Price Target	Buy	$20.00	High	i Rating by Jason Kolbert at Maxim Group
6/19/2017	Maxim Group	Upgrade	Hold ➝ Buy	$20.00	Low	i Rating by Jason Kolbert at Maxim Group
5/22/2017	Maxim Group	Reiterated Rating	Hold		Low	i Rating by Jason Kolbert at Maxim Group
5/15/2017	HC Wainwright	Reiterated Rating	Buy	$35.00	Low	i Rating by Swayampakula Ramakanth at HC Wainwright
5/5/2017	HC Wainwright	Reiterated Rating	Buy	$35.00	Low	i Rating by Swayampakula Ramakanth at HC Wainwright
5/4/2017	Maxim Group	Reiterated Rating	Hold		Low	i Rating by Jason Kolbert at Maxim Group
2/13/2017	Maxim Group	Downgrade	Buy ➝ Hold		N/A	i Rating by Jason Kolbert at Maxim Group
2/11/2017	HC Wainwright	Set Price Target	Buy	$40.00	N/A	i Rating by Swayampakula Ramakanth at HC Wainwright
1/17/2017	Maxim Group	Set Price Target	Buy	$30.00	N/A	i Rating by Jason Kolbert at Maxim Group
1/10/2017	(FBRC)	Reiterated Rating	Buy		N/A	i Rating by Vernon Bernardino at (FBRC)
12/23/2016	(FBRC)	Reiterated Rating	Outperform	$60.00	N/A	i Rating by Vernon Bernardino at (FBRC)
11/2/2016	Maxim Group	Set Price Target	Buy	$30.00	N/A	i Rating by Jason Kolbert at Maxim Group
9/12/2016	Maxim Group	Reiterated Rating	Buy	$30.00	N/A	i Rating by Jason Kolbert at Maxim Group
8/4/2016	HC Wainwright	Reiterated Rating	Buy	$35.00	N/A	i
7/27/2016	Maxim Group	Reiterated Rating	Buy		N/A	i Rating by Jason Kolbert at Maxim Group
7/19/2016	HC Wainwright	Reiterated Rating	Buy	$35.00	N/A	i Rating by S. Ramakanth at HC Wainwright
7/11/2016	Maxim Group	Reiterated Rating	Buy	$30.00	N/A	i Rating by Jason Kolbert at Maxim Group
7/11/2016	(FBRC)	Reiterated Rating	Buy		N/A	i Rating by Vernon Bernardino at (FBRC)
6/22/2016	Maxim Group	Reiterated Rating	Buy	$30.00	N/A	i Rating by Jason Kolbert at Maxim Group
6/22/2016	(FBRC)	Reiterated Rating	Outperform	$60.00	N/A	i Rating by Vernon Bernardino at (FBRC)
5/16/2016	Maxim Group	Reiterated Rating	Buy		N/A	i Rating by Jason Kolbert at Maxim Group

(Data available from 5/16/2016 forward)

Pluristem Therapeutics, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

Today's Range

Now: $3.65

$3.51

$3.84

50 Day Range

MA: $4.40

$3.54

$5.04

52 Week Range

Now: $3.65

$3.50

$12.15

Volume

284,624 shs

Average Volume

647,958 shs

Market Capitalization

$115.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Pluristem Therapeutics?

The following Wall Street analysts have issued stock ratings on Pluristem Therapeutics in the last twelve months: Alliance Global Partners, Dawson James, HC Wainwright, Jefferies Financial Group Inc., and Zacks Investment Research.
View the latest analyst ratings for PSTI.

What is the current price target for Pluristem Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Pluristem Therapeutics in the last year. Their average twelve-month price target is $9.88, suggesting a possible upside of 170.5%. Alliance Global Partners has the highest price target set, predicting PSTI will reach $12.50 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $6.00 for Pluristem Therapeutics in the next year.
View the latest price targets for PSTI.

What is the current consensus analyst rating for Pluristem Therapeutics?

Pluristem Therapeutics currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PSTI will outperform the market and that investors should add to their positions of Pluristem Therapeutics.
View the latest ratings for PSTI.

What other companies compete with Pluristem Therapeutics?

Other companies that are similar to Pluristem Therapeutics include Aptose Biosciences, Oyster Point Pharma, Gritstone bio, AVROBIO, Codiak BioSciences, Jounce Therapeutics, Solid Biosciences, Lineage Cell Therapeutics, Outlook Therapeutics, Opthea, Adverum Biotechnologies, Fusion Pharmaceuticals, Surface Oncology, SQZ Biotechnologies and Autolus Therapeutics.

How do I contact Pluristem Therapeutics' investor relations team?

Pluristem Therapeutics' physical mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 3508409. The biotechnology company's listed phone number is 972747108600 and its investor relations email address is [email protected] The official website for Pluristem Therapeutics is www.pluristem.com.